(Q46775891)

25 December 2017

title

Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension (English)

1 reference

25 December 2017

author name string

L H Opie

series ordinal

1

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

25 December 2017

published in

The Lancet

1 reference

25 December 2017

volume

358

1 reference

25 December 2017

issue

9296

1 reference

25 December 2017

page(s)

1829-1831

1 reference

25 December 2017

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Guidelines for management of hypertension: report of the third working party of the British Hypertension Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906879-9

7 January 2021

10.1016/S0140-6736(01)06879-9

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

11741617

1 reference

25 December 2017